Sep 2026
Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial.
Evaluated the immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) compared with MF59-adjuvanted egg-derived quadrivalent influenza vaccine (aQIV) and recombinant quadrivalent influenza vaccine (QIVr) in adults aged 50 years or older.
Brandon J. Essink, Wim Vermeulen, Coralie Andrade et al.
· Lancet. Infectious Diseases... · 1 citation